CARNA BIOSCIENCES

Consolidated Financial Results for the Second Quarter of the Year Ending December 31, 2026

[Japanese GAAP]

August 6, 2026

Company name: Carna Biosciences, Inc. Stock Exchange listing: Tokyo Stock Exchange (Growth)
Stock code: 4572 URL: https://www.carnabio.com/english/
Representative: Kohichiro Yoshino, President and CEO
Contact: Emi Yamamoto, Director, Business Administration Division TEL: +81-78-302-7075

Scheduled submission of quarterly report: August 7, 2026
Scheduled date of dividend payment: –
Supplementary materials for financial results: Yes
Financial results briefing: Yes

(Rounded down to the nearest million yen)

1. Consolidated Financial Results for the Six Months Ended June 30, 2026

(1) Consolidated operating results (Percentages show changes from the same period of the previous fiscal year)

	Net sales		Operating profit		Ordinary profit		Profit attributable to owners of parent	
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%
Six months ended June 30, 2026	401	59.8	(954)	—	(1,005)	—	(1,039)	—
Six months ended June 30, 2025	251	(20.4)	(1,052)	—	(1,055)	—	(1,056)	—

Note: Comprehensive income Six months ended June 30, 2026: (1,026) million yen (–%)
Six months ended June 30, 2025: (1,086) million yen (–%)

	Basic earnings per share	Diluted earnings per share
	Yen	Yen
Six months ended June 30, 2026	(53.13)	—
Six months ended June 30, 2025	(55.29)	—

(2) Consolidated financial position

	Total assets	Net assets	Equity-to-asset ratio
	Millions of yen	Millions of yen	%
As of June 30, 2026	1,765	(407)	(23.9)
As of December 31, 2025	1,229	309	25.1

Reference: Shareholders' equity As of June 30, 2026: (422) million yen As of Dec. 31, 2025: 309 million yen

2. Dividends

	Dividend per share				
	End of 1st quarter	End of 2nd quarter	End of 3rd quarter	Year–end	Total
	Yen	Yen	Yen	Yen	Yen
FY2025	—	0.00	—	0.00	0.00
FY2026	—	0.00			
FY2026 (Forecast)			–	0.00	0.00

Note: Revision to the most recently announced dividend forecast: None

3. Consolidated Financial Forecast for FY2026 (January 1, 2026 to December 31, 2026)

(Percentages show changes from the same period of the previous fiscal year)

	Net sales		Operating income		Ordinary income		Profit attributable to owners of parent		Earnings per share
	Millions of yen	%	Millions of yen	%	Millions of yen	%	Millions of yen	%	Yen
FY2026	720	24.4	(2,028)	—	(2,053)	—	(2,090)	—	(108.95)

Note: Revision to the most recently announced financial forecast: None

*** Notes**

(1) Changes in significant subsidiaries during the period (changes in specified subsidiaries resulting in the change in the scope of consolidation): None

(2) Application of special accounting methods for presenting quarterly consolidated financial statements: None

(3) Changes in accounting policies, accounting estimates, and restatements

1) Changes in accounting policies due to revisions in accounting standards, etc.: None

2) Changes in accounting policies other than 1) above: None

3) Changes in accounting estimates: None

4) Restatements: None

(4) Number of shares outstanding (common stock)

1) Number of shares outstanding at the end of the period (including treasury stock)

As of June 30, 2026:	20,652,469 shares	As of Dec. 31, 2025:	19,150,500 shares

2) Number of treasury stock at the end of the period

As of June 30, 2026:	11,144 shares	As of Dec. 31, 2025:	11,136 shares

3) Average number of shares outstanding during the period

First six months of FY2026:	19,571,658 shares	First six months of FY2025:	19,098,719 shares

* This financial report is exempt from quarterly review procedures by auditors.

* Note to ensure appropriate use of forecasts and other remarks

The forecasts and other forward-looking statements included in this document are based on the information currently available to the management and certain assumptions considered by the management to be reasonable. Actual operating results may differ materially from these statements for various factors.

Contents

Consolidated Financial Statements

(1) Consolidated Balance Sheet

(Thousands of yen)

	FY2025 (As of Dec. 31, 2025)	FY2026 (As of Jun. 30, 2026)
Assets		
Current assets		
Cash and deposits	516,789	1,100,479
Accounts receivable–trade	100,528	116,403
Merchandise and finished goods	106,302	103,747
Work in process	11,609	11,486
Raw materials and supplies	36,190	34,899
Advance payments-trade	261,308	264,530
Prepaid expenses	66,408	46,020
Other	76,389	22,912
Total current assets	1,175,527	1,700,480
Non-current assets		
Investments and other assets	54,121	65,022
Total non-current assets	54,121	65,022
Total assets	1,229,648	1,765,502

(Thousands of yen)

	FY2025 (As of Dec. 31, 2025)	FY2026 (As of Jun. 30, 2026)
Liabilities		
Current liabilities		
Accounts payable–trade	477	223
Current portion of long-term borrowings	8,410	—
Lease liabilities	8,491	8,689
Accounts payable-other	138,665	109,353
Income taxes payable	2,079	10,008
Other	9,946	12,467
Total current liabilities	168,070	140,741
Non-current liabilities		
Bonds payable	—	1,734,375
Convertible-bond-type bonds with share acquisition rights	681,250	231,249
Lease liabilities	16,336	11,941
Asset retirement obligations	54,452	54,968
Other	321	67
Total non-current liabilities	752,360	2,032,601
Total liabilities	920,430	2,173,343
Net assets		
Shareholders' equity		
Capital stock	14,846	161,961
Capital surplus	2,196,625	2,343,740
Retained earnings	(1,980,588)	(3,020,371)
Treasury shares	(227)	(231)
Total shareholders' equity	230,655	(514,899)
Accumulated other comprehensive income		
Valuation difference on available-for-sale securities	(2,862)	229
Foreign currency translation adjustment	81,424	91,989
Total accumulated other comprehensive income	78,562	92,219
Share acquisition rights	—	14,840
Total net assets	309,217	(407,840)
Total liabilities and net assets	1,229,648	1,765,502

(2) Consolidated Statements of Income and Comprehensive Income

Consolidated Statement of Income

(Thousands of yen)

	First six months of FY2025 (Jan. 1 – Jun. 30, 2025)	First six months of FY2026 (Jan. 1 – Jun. 30, 2026)
Net sales	251,097	401,154
Cost of sales	77,358	108,648
Gross profit	173,738	292,505
Selling, general and administrative expenses	1,226,580	1,246,617
Operating loss	(1,052,841)	(954,112)
Non-operating income		
Interest income	2,999	819
Dividend income	1,528	1,300
Other	98	2,243
Total non-operating income	4,626	4,362
Non-operating expenses		
Interest expenses	895	34,219
Guarantee commission	198	165
Share issuance costs	91	936
Share acquisition rights issuance costs	—	11,613
Foreign exchange losses	5,624	9,113
Total non-operating expenses	6,809	56,048
Ordinary loss	(1,055,024)	(1,005,798)
Extraordinary losses		
Impairment losses	315	12,350
Loss on redemption of bonds	—	20,138
Total extraordinary losses	315	32,489
Loss before income taxes	(1,055,340)	(1,038,288)
Income taxes-current	1,985	1,494
Income taxes-deferred	(1,270)	—
Total income taxes	714	1,494
Loss	(1,056,054)	(1,039,782)
Loss attributable to owners of parent	(1,056,054)	(1,039,782)

Consolidated Statement of Comprehensive Income

(Thousands of yen)

	First six months of FY2025 (Jan. 1 – Jun. 30, 2025)	First six months of FY2026 (Jan. 1 – Jun. 30, 2026)
Loss	(1,056,054)	(1,039,782)
Other comprehensive income		
Valuation difference on available-for-sale securities	(2,737)	3,092
Foreign currency translation adjustment	(27,431)	10,564
Total other comprehensive income	(30,169)	13,656
Comprehensive income	(1,086,224)	(1,026,125)
Comprehensive income attributable to owners of parent	(1,086,224)	(1,026,125)
Comprehensive income attributable to non-controlling interests	—	—

(3) Consolidated Statement of Cash Flows

(Thousands of yen)

	First six months of FY2025 (Jan. 1 – Jun. 30, 2025)	First six months of FY2026 (Jan. 1 – Jun. 30, 2026)
Cash flows from operating activities		
Profit (loss) before income taxes	(1,055,340)	(1,038,288)
Impairment loss	315	12,350
Interest income	(2,999)	(819)
Dividend income	(1,528)	(1,300)
Interest expenses	895	34,219
Share-based payment expenses	11,150	5,301
Share issuance costs	91	936
Share acquisition rights issuance costs	—	11,613
Loss on redemption of bonds	—	20,138
Foreign exchange losses (gains)	1,029	3,583
Decrease (increase) in trade receivables	11,624	(14,697)
Decrease (increase) in inventories	(9,446)	3,968
Increase (decrease) in trade payables	(1,694)	(254)
Increase (decrease) in accounts payable–other	(21,825)	(31,111)
Decrease (increase) in advance payments to suppliers	37,391	(3,222)
Other, net	34,825	85,900
Subtotal	(995,509)	(911,678)
Interest received	4,098	1,913
Interest paid	(887)	(3,010)
Income taxes refund (paid)	(2,341)	(2,150)
Net cash provided by (used in) operating activities	(994,641)	(914,926)
Cash flows from investing activities		
Purchase of property, plant and equipment	(140)	(4,787)
Expense by an increase in long-term prepayment cost	—	(5,848)
Purchase of investment securities	(15,743)	—
Other, net	—	41
Net cash provided by (used in) investing activities	(15,884)	(10,593)
Cash flows from financing activities		
Repayments of long-term borrowings	(9,996)	(8,410)
Proceeds from issuance of bonds	—	1,711,250
Redemption of convertible bonds	—	(250,000)
Proceeds from issuance of shares resulting from exercise of share acquisition rights	—	31,374
Proceeds from stock issuance to a third party	—	19,869
Proceeds from issuance of share acquisition rights	—	3,611
Other, net	(4,010)	(4,200)
Net cash provided by (used in) financing activities	(14,006)	1,503,494
Effect of exchange rate change on cash and cash equivalents	(23,384)	5,715
Net increase (decrease) in cash and cash equivalents	(1,047,915)	583,689
Cash and cash equivalents at beginning of period	2,108,484	516,789
Cash and cash equivalents at end of period	1,060,569	1,100,479

This financial report is solely a translation of "Kessan Tanshin" (in Japanese, including attachments), which has been prepared in accordance with accounting principles and practices generally accepted in Japan, for the convenience of readers who prefer an English translation.